Plain-English translation of NCT07382726 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Phase 1 โ Testing in a small group (usually 20โ80 people) to find a safe dose and watch for side effects.
This is an early-stage study testing whether izalontamab brengitecan, a new medication, works better when combined with in people with advanced lung cancer. Your cancer must have a specific genetic change (called KRAS G12C) and must have stopped responding to a previous KRAS inhibitor. The study will watch carefully for side effects and see if this combination helps shrink tumors.
Some patients with this type of lung cancer eventually stop responding to the first KRAS inhibitor they try. This study is exploring whether adding a second medication might help those patients whose cancer has become resistant to the initial treatment.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
You will receive two medications: a pill () that you take by mouth twice daily continuously, and an intravenous infusion (izalontamab brengitecan) given on Day 1 and Day 8 of each 21-day cycle. The study will monitor your health closely with blood tests and scans to check if the cancer is shrinking and to watch for any side effects. You'll be part of a small group of about 18 patients, and the study team will closely track how well the treatment works and your overall safety.
AI-generated summary from trial data ยท Nov 17, 2026 ยท Not medical advice
United States